Aiqi Zhao Mingzhe Zhao Wenbin Qian Aibin Liang Ping Li Hui Liu
10.3389/fimmu.2022.1063986
Front Immunol
2023 Jan 13;13:1063986.
cellular immunotherapy chimeric antigen receptor t cells (car t) late effects refractory/relapsed b-cell lymphoma second cancer therapy-related acute myeloid leukemia (t-aml) therapy-related myelodysplastic syndrome (t-mds)
CC BY
https://pubmed.ncbi.nlm.nih.gov/36713414/
Hematopoietic Stem Cell Transplantation Lymphoma Lymphoma, B-Cell Myelodysplastic Syndromes / therapy Myeloproliferative Disorders Neoplasms, Second Primary / etiology Neoplasms, Second Primary / therapy Receptors, Chimeric Antigen
Hematopoietic Stem Cell Transplantation Lymphoma Lymphoma, B-Cell Myelodysplastic Syndromes / therapy Myeloproliferative Disorders Neoplasms, Second Primary / etiology Neoplasms, Second Primary / therapy Receptors, Chimeric Antigen Review Research Support, Non-U.S. Gov't Aged Antigens, CD19 Female Humans Immunotherapy, Adoptive / adverse effects Male Middle Aged Receptors, Chimeric Antigen Antigens, CD19
PMC9880439
36713414
Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature
2023